rozrolimupab

Known as: Symphoglobulin-D 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2010-2012
01220102012

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
INTRODUCTION Over the last decade the field of medicine has dramatically changed with the introduction of biological therapies… (More)
Is this relevant?
2012
2012
Rozrolimupab, a recombinant mixture of 25 fully human RhD-specific monoclonal antibodies, represents a new class of recombinant… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
Is this relevant?
2012
2012
In this issue of Blood, Robak et al present data suggesting that rozrolimupab, a firstin-class mixture of 25 recombinant… (More)
Is this relevant?
2011
2011
The beneficial effect of antibody therapy in human disease has become well established mainly for the treatment of cancer and… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table I
Is this relevant?
2010
2010
Currently under codevelopment by Symphogen and Swedish Orphan Biovitrum, rozrolimupab is the first in a new class of recombinant… (More)
Is this relevant?